Skip to content

Contrast-enhanced Ultrasound for Sentinel Node Detection

Contrast-enhanced Ultrasound for Sentinel Node Detection in Patients With Melanoma, Breast Cancer or Head & Neck Cancer

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07310758
Enrollment
91
Registered
2025-12-30
Start date
2025-09-18
Completion date
2026-09-18
Last updated
2025-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma, Breast Cancer, Head & Neck Cancer

Keywords

contrast-enhanced ultrasound

Brief summary

This is a prospective single-center interventional non-inferiority study where subjects are participating for one day for patients 18 years or older with melanoma, breast cancer or head & neck cancer (including melanoma of head and neck area) and scheduled for a surgical SN procedure in the NKI-AvL without any contra-indication for Sonazoid contrast agent, such as an allergy to eggs or egg products. The primary objective is to assess the sensitivity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid). Secondary objectives are the specificity of CEUS for intra-operative SN localization, the time required to localize the SNs using CEUS and intraoperative usability of the CEUS-system. The primary endpoint is the sensitivity of the CEUS SN localization method. The conventional gamma probe will be used as ground truth comparison.

Interventions

Intradermal injection of the ultrasound contrast agent Sonazoid.

Sponsors

GE Healthcare
CollaboratorINDUSTRY
The Netherlands Cancer Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years or older * Patient has been diagnosed with cancer in the skin (melanoma), breast or head & neck (including melanoma of head and neck area) * In case of a melanoma: it should be located in the limbs or head and neck area * Scheduled for a surgical SN procedure at the NKI-AvL * Patient provides written informed consent

Exclusion criteria

* Pregnancy * Any known clinically significant acute hypersensitivity reaction to the study medication, such as eggs or egg products * Other contra-indications for Sonazoid contrast agent, including arteriovenous cardiac or pulmonary shunt, serious coronary arterial disease and serious pulmonary disease

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of the CEUS SN localization method1 dayTo assess the sensitivity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid). Could CEUS replace the conventional radioactive technetium method?

Secondary

MeasureTime frameDescription
Specificity of the CEUS SN localization method1 daySpecificity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid)
Time in minutes1 dayTime required to localize the SNs using CEUS.
System-usability score (SUS) and questionnaire for the surgeon.1 dayIntraoperative usability of the CEUS-system.

Countries

Netherlands

Contacts

Primary ContactMarijn Hiep
ma.hiep@nki.nl+31205121751

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026